KR890002222A - Dementia Treatment - Google Patents

Dementia Treatment Download PDF

Info

Publication number
KR890002222A
KR890002222A KR1019870006819A KR870006819A KR890002222A KR 890002222 A KR890002222 A KR 890002222A KR 1019870006819 A KR1019870006819 A KR 1019870006819A KR 870006819 A KR870006819 A KR 870006819A KR 890002222 A KR890002222 A KR 890002222A
Authority
KR
South Korea
Prior art keywords
group
hydrogen atom
hydroxymethyl
aralkyl
adenosine derivative
Prior art date
Application number
KR1019870006819A
Other languages
Korean (ko)
Other versions
KR950007909B1 (en
Inventor
마사요시 고또
노부다까 데무라
쓰또무 오사끼
Original Assignee
훽스트 재팬 리미티드
알프레드 딘스트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 훽스트 재팬 리미티드, 알프레드 딘스트 filed Critical 훽스트 재팬 리미티드
Priority to KR1019870006819A priority Critical patent/KR950007909B1/en
Publication of KR890002222A publication Critical patent/KR890002222A/en
Application granted granted Critical
Publication of KR950007909B1 publication Critical patent/KR950007909B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

내용 없음.No content.

Description

치매 치료제Dementia Treatment

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (12)

활성성분으로서 하기 일반식(Ⅰ)의 아데노신 유도체를 함유함을 특징으로 하는 치매 치료제.A therapeutic agent for dementia characterized by containing an adenosine derivative of the following general formula (I) as an active ingredient. 상기식에서, R1은 수소원자 또는 할로겐원자이며, R2는 수소원자, 알킬그룹, 사이클로알킬그룹 또는 아르알킬그룹이고, R3는 하이드록시메틸그룹 또는 -CONHR4그룹(여기서, R4는 수소원자, 알킬그룹, 사이클로알킬그룹 또는 아르알킬그룹이다)이며, 단 R1과 R2가 모두 수소원자이고 R3가 하이드록시메틸그룹인 경우는 제외된다.Wherein R 1 is a hydrogen atom or a halogen atom, R 2 is a hydrogen atom, an alkyl group, a cycloalkyl group or an aralkyl group, R 3 is a hydroxymethyl group or a -CONHR 4 group (wherein R 4 is hydrogen Atom, alkyl group, cycloalkyl group, or aralkyl group), except that R 1 and R 2 are both hydrogen atoms and R 3 is hydroxymethyl group. 제1항에 있어서, 일반식(Ⅰ)의 아데노신 유도체에서 R1이 할로겐원자이며, R2가 수소원자이고, R3가 하이드록시메틸그룹인 치매 치료제.The agent for treating dementia according to claim 1, wherein in the adenosine derivative of formula (I), R 1 is a halogen atom, R 2 is a hydrogen atom, and R 3 is a hydroxymethyl group. 제2항에 있어서, 아데노신 유도체에서 R1이 염소원자인 치매 치료제.The agent for treating dementia according to claim 2, wherein R 1 in the adenosine derivative is a chlorine atom. 제1항에 있어서, 일반식(Ⅰ)의 아데노신 유도체에서 R1이 수소원자이며, R2가 알킬그룹, 사이클로알킬그룹 또는 아르알킬그룹이고, R3가 하이드록시메틸그룹인 치매 치료제.The agent for treating dementia according to claim 1, wherein in the adenosine derivative of formula (I), R 1 is a hydrogen atom, R 2 is an alkyl group, a cycloalkyl group or an aralkyl group, and R 3 is a hydroxymethyl group. 제4항에 있어서, R2가 사이클로알킬그룹 또는 아르알킬그룹인 치매 치료제.The therapeutic agent for dementia according to claim 4, wherein R 2 is a cycloalkyl group or an aralkyl group. 제1항에 있어서, 일반식(Ⅰ)의 아데노신 유도체에서 R1및 R2가 각각 수소원자이며, R3가 -CONHR4그룹(여기서, R4는 수소원자, 알킬그룹, 사이클로알킬그룹 또는 아르알킬그룹이다)인 치매 치료제.The compound of claim 1, wherein in the adenosine derivative of formula (I), R 1 and R 2 are each a hydrogen atom, and R 3 is a -CONHR 4 group wherein R 4 is a hydrogen atom, an alkyl group, a cycloalkyl group or Alkyl group). 치매 치료활성이 있는 약제를 제조하기 위한 하기 일반식(Ⅰ) 화합물의 용도.Use of the following general formula (I) compound for the manufacture of a medicament with dementia therapeutic activity. 상기식에서, R1은 수소원자 또는 할로겐원자이며, R2는 수소원자, 알킬그룹, 사이클로알킬그룹 또는 아르알킬그룹이고, R3는 하이드록시메틸그룹 또는 -CONHR4그룹(여기서, R4는 수소원자, 알킬그룹, 사이클로알킬그룹 또는 아르알킬그룹이다)이며, 단 R1과 R2가 모두 수소원자이고 R3가 하이드록시메틸그룹인 경우는 제외된다.Wherein R 1 is a hydrogen atom or a halogen atom, R 2 is a hydrogen atom, an alkyl group, a cycloalkyl group or an aralkyl group, R 3 is a hydroxymethyl group or a -CONHR 4 group (wherein R 4 is hydrogen Atom, alkyl group, cycloalkyl group, or aralkyl group), except that R 1 and R 2 are both hydrogen atoms and R 3 is hydroxymethyl group. 제7항에 있어서, R1이 할로겐원자이고, R2가 수소원자이며, R3가 하이드록시메틸그룹인 일반식(Ⅰ)의 아데노신 유도체의 용도.8. The use of the adenosine derivative of formula (I) according to claim 7, wherein R 1 is a halogen atom, R 2 is a hydrogen atom and R 3 is a hydroxymethyl group. 제8항에 있어서, 아데노신 유도체에서 R1이 염소원자인 화합물의 용도.Use of a compound according to claim 8 wherein R 1 is a chlorine atom in an adenosine derivative. 제7항에 있어서, R1이 수소원자이며, R2가 알킬그룹, 사이클로알킬그룹 또는 아르알킬그룹이고, R3가 하이드록시메틸그룹인 일반식(Ⅰ)의 아데노신 유도체의 용도.Use of the adenosine derivative of formula (I) according to claim 7, wherein R 1 is a hydrogen atom, R 2 is an alkyl group, a cycloalkyl group or an aralkyl group, and R 3 is a hydroxymethyl group. 제10항에 있어서, R2가 사이클로알킬그룹 또는 아르알킬그룹인 화합물의 용도.Use of a compound according to claim 10 wherein R 2 is a cycloalkyl group or an aralkyl group. 제7항에 있어서, R1및 R2가 각각 수소원자이며, R3가 -CONHR4그룹(여기서, R4는 수소원자, 알킬그룹, 사이클로알킬그룹 또는 아르알킬그룹이다)인 일반식(Ⅰ)의 아데노신 유도체의 용도.8. A general formula (I) according to claim 7, wherein R 1 and R 2 are each hydrogen atoms, and R 3 is a -CONHR 4 group, wherein R 4 is a hydrogen atom, an alkyl group, a cycloalkyl group or an aralkyl group. Use of adenosine derivatives). ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019870006819A 1987-07-01 1987-07-01 Anti-dementia agents KR950007909B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019870006819A KR950007909B1 (en) 1987-07-01 1987-07-01 Anti-dementia agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019870006819A KR950007909B1 (en) 1987-07-01 1987-07-01 Anti-dementia agents

Publications (2)

Publication Number Publication Date
KR890002222A true KR890002222A (en) 1989-04-08
KR950007909B1 KR950007909B1 (en) 1995-07-21

Family

ID=19262003

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870006819A KR950007909B1 (en) 1987-07-01 1987-07-01 Anti-dementia agents

Country Status (1)

Country Link
KR (1) KR950007909B1 (en)

Also Published As

Publication number Publication date
KR950007909B1 (en) 1995-07-21

Similar Documents

Publication Publication Date Title
KR880009951A (en) N-Indanyl carboxyamide derivatives and agricultural / horticultural fungicides containing the derivatives as active ingredients
FR2361901A1 (en) NUCLEOTIDES SUBSTITUTION DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THESE SUBSTANCES
KR940005274A (en) Sjoegren Syndrome Treatment
KR890011596A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for treating insomnia
KR950016727A (en) How to increase thrombomodulin expression
KR910004191A (en) Renal disease treatment
KR950702530A (en) Prostaglandin derivatives
KR900007415A (en) Amnesiac improver
KR890008136A (en) Antimicrobial 9-Deoxo-9a-allyl and propargyl-9a-aza-9a-homoerythromycin A derivatives
IL89324A0 (en) Therapeutic agents for the treatment of peptic ulcer disease containing xanthine derivatives
KR880001596A (en) Dihydropyridine Compound-containing Brain Dysfunction
KR890002222A (en) Dementia Treatment
ES2032797T3 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF ULCERA PEPTICA DISEASE.
DK601583A (en) CARBAMYLOXYBENZHYDROLD DERIVATIVES
KR850006429A (en) New cyanoimidazole nucleoside derivatives and preparation method thereof
KR970064604A (en) Benzopyran derivatives and their use as therapeutic agents for heart disease
KR900701273A (en) Anti-Ecstatic Ergoline Derivatives
KR890003372A (en) Atherosclerosis therapy with pyrimido [2,1-b] benzothiazole derivatives
ATE144900T1 (en) USE OF XANTHINE DERIVATIVES AGAINST STOMACH ULCER
KR890016027A (en) Benzthiazole Fungicide
KR900016130A (en) 2-pyridylmethylthio derivatives and ulcer treatments
KR890001543A (en) Diabetes treatment
KR920019349A (en) Use of R (+)-3-amino-1-hydroxy-pyrrolidin-2-one to treat anxiety
KR920019354A (en) Use for the treatment of AIDS of 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
ATE81466T1 (en) USE OF 2-OXO-IMIDAZOLIDINE DERIVATIVES IN THE PROPHYLAXIS AND TREATMENT OF HEART FAILURE.

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090708

Year of fee payment: 15

EXPY Expiration of term